XPOVIO
Total Payments
$46.3M
Transactions
31,225
Doctors
7,608
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.0M | 7,062 | 2,874 |
| 2023 | $7.0M | 7,241 | 3,286 |
| 2022 | $9.8M | 6,517 | 2,925 |
| 2021 | $12.6M | 5,936 | 2,261 |
| 2020 | $11.8M | 4,469 | 1,753 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39.0M | 6,499 | 84.4% |
| Honoraria | $4.5M | 1,540 | 9.7% |
| Consulting Fee | $1.1M | 464 | 2.3% |
| Food and Beverage | $602,075 | 20,925 | 1.3% |
| Travel and Lodging | $570,945 | 1,058 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $182,200 | 56 | 0.4% |
| Charitable Contribution | $150,000 | 1 | 0.3% |
| Grant | $70,000 | 3 | 0.2% |
| Education | $61,781 | 659 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,953 | 13 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $14,175 | 7 | 0.0% |
Payments by Type
Research
$39.0M
6,499 transactions
General
$7.2M
24,726 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2 Study of Selinexor in Combination with SOC Therapy for Newly Diagnosed or Recurrent Glioblastoma | Karyopharm Therapeutics Inc. | $5.0M | 0 |
| XPORT-COV-1001 | Karyopharm Therapeutics Inc. | $3.5M | 0 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | Karyopharm Therapeutics Inc. | $2.3M | 0 |
| A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer | Karyopharm Therapeutics Inc. | $2.1M | 1 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies | Karyopharm Therapeutics Inc. | $1.9M | 0 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Karyopharm Therapeutics Inc. | $1.8M | 0 |
| A phase 2 open-label multicenter study to evaluate the safety and efficacy of selinexor + pembrolizumab in recurrent advanced melanoma | Karyopharm Therapeutics Inc. | $1.8M | 0 |
| KCP-330-020 | Karyopharm Therapeutics Inc. | $1.7M | 0 |
| A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) | Karyopharm Therapeutics Inc. | $1.7M | 0 |
| A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma | Karyopharm Therapeutics Inc. | $1.6M | 0 |
| A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR WITH OR WITHOUT PEMBROLIZUMAB VERSUS STANDARD OF CARE IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER WITH RAS MUTATIONS | Karyopharm Therapeutics Inc. | $1.0M | 0 |
| A Phase 2B study of selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide in patients with multiple myeloma relapsing on current therapy | Karyopharm Therapeutics Inc. | $983,226 | 0 |
| KCP-330-017A | Karyopharm Therapeutics Inc. | $831,280 | 0 |
| A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma | Karyopharm Therapeutics Inc. | $828,550 | 0 |
| A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Karyopharm Therapeutics Inc. | $784,107 | 0 |
| KCP-330-024 | Karyopharm Therapeutics Inc. | $625,379 | 0 |
| A phase 2, randomized, open-label, multicenter study of Selinexor or Physicians choice in patients with myelofibrosis | Karyopharm Therapeutics Inc. | $589,757 | 0 |
| 3300012 | Karyopharm Therapeutics Inc. | $585,610 | 0 |
| Phase 1/2 Trial of Selinexor in COmbination with Carfilzomib, Pomalidomide and DexamethasonE (SCOPE) for Patients with Proteasome-inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma | Karyopharm Therapeutics Inc. | $562,224 | 0 |
| KCP-330-012 | Karyopharm Therapeutics Inc. | $539,046 | 0 |
Top Doctors Receiving Payments for XPOVIO — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Military Health Care Provider | Boston, MA | $13,852 | 12 |
| , MD | Hematology & Oncology | Atascocita, TX | $13,567 | 19 |
| , M.D | Internal Medicine | Miami, FL | $13,543 | 20 |
| , M.D | Gynecologic Oncology | New York, NY | $13,477 | 10 |
| , M.D | Medical Oncology | Tampa, FL | $12,959 | 13 |
| , MD | Hematology & Oncology | New York, NY | $12,738 | 7 |
| , NP-C | Family | Newark, DE | $12,713 | 36 |
| , MD | Medical Oncology | New York, NY | $12,518 | 5 |
| , MD | Hematology & Oncology | New York, NY | $11,744 | 8 |
| , NP | Nurse Practitioner | Richmond, VA | $11,653 | 23 |
| , M.D | Hematology & Oncology | Houston, TX | $11,625 | 1 |
| , MD | Medical Oncology | Saint Louis, MO | $10,595 | 2 |
| , N.P | Acute Care | Los Angeles, CA | $10,376 | 16 |
| , M.D | Medical Oncology | New York, NY | $10,329 | 8 |
| , MBBS | Hematology & Oncology | Houston, TX | $10,256 | 3 |
| , MD | Medical Oncology | New York, NY | $10,086 | 5 |
| , M.D | Internal Medicine | New York, NY | $9,900 | 3 |
| , M.D | Internal Medicine | Duarte, CA | $9,871 | 3 |
| , M.D., | Hematology & Oncology | New York, NY | $9,716 | 11 |
| , MD | Hematology & Oncology | Noblesville, IN | $9,659 | 9 |
| , PA-C | Physician Assistant | Ramsey, MN | $9,465 | 17 |
| , APRN | Registered Nurse First Assistant | Ogden, UT | $9,311 | 18 |
| , MD | Hematology & Oncology | New Orleans, LA | $9,297 | 11 |
| , MD | Internal Medicine | New York, NY | $9,137 | 3 |
| , APRN | Family | Salt Lake City, UT | $8,999 | 16 |
Ad
Manufacturing Companies
- Karyopharm Therapeutics Inc. $46.3M
Product Information
- Type Drug
- Total Payments $46.3M
- Total Doctors 7,608
- Transactions 31,225
About XPOVIO
XPOVIO is a drug associated with $46.3M in payments to 7,608 healthcare providers, recorded across 31,225 transactions in the CMS Open Payments database. The primary manufacturer is Karyopharm Therapeutics Inc..
Payment data is available from 2020 to 2024. In 2024, $5.0M was paid across 7,062 transactions to 2,874 doctors.
The most common payment nature for XPOVIO is "Unspecified" ($39.0M, 84.4% of total).
XPOVIO is associated with 20 research studies, including "A Phase 1/2 Study of Selinexor in Combination with SOC Therapy for Newly Diagnosed or Recurrent Glioblastoma" ($5.0M).